罗氏将肥胖资产CT-388转入第三阶段

2025-09-23 00:12

Roche (OTCQX:RHHBY) has advanced CT-388, a dual GLP-1 and GIP receptor agonist/modulator, into phase 3.
The announcement was made during Roche Pharma Day in London on Monday.
"Our goal is to become a Top 3 player (in the obesity drug market), and I want you to know I'm serious about this goal," Roche Pharmaceuticals CEO Teresa Graham said, Reuters reported.
During her presentation, Graham noted that the company has six assets in the pipeline for obesity and conditions linked to it, such as type 2 diabetes, adding they could all hit the market by 2030, with some potentially becoming blockbusters.
In March, Roche signed a licensing deal with Zealand Pharma (OTCPK:ZLDPF) to co-develop and co-commercialize the latter's petrelintide, an amylin analog, as a standalone therapy and a fixed-dose combination with CT-388.
The Swiss pharma acquired CT-388 through its September 2024 acquisition of Carmot Therapeutics.

More on Roche